Ahmar Jan Qureshi

Dr. Ahmar Jan Qureshi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2026 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
AKAbdul Qayum Khan
Abdul Qayum Khan

30 April 2026 in Endocrinology, Diabetes & Metabolism
Verified
Journal Article
Open access
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MTMuhammad Riyyan Tariq Tagga
Muhammad Riyyan Tariq Tagga
RMRaghabendra Kumar Mahato
Raghabendra Kumar Mahato
Introduction: This critique examines the methodological quality of a recent study by Shahid et al. on mortality trends related to peripheral circulatory complications in patients with type 2 diabetes mellitus using the CDC WONDER database. Methods: We critically appraised the original study's methodology, including the consistency of reported mortality rates, age group data presentation, classification of urban and rural areas, reporting of race and ethnicity data, place of death analysis and causal inferences drawn from the ecological design. Results: Several methodological shortcomings were identified: inconsistent reporting of mortality rate denominators (per 100,000 vs. per 1,000,000 population); selective reporting of age group data in the main text; use of a non‐standard threshold (500,000 population) for classifying urban and rural areas; inconsistent use of the ‘Non‐Hispanic’ qualifier for race and ethnicity categories; percentages summing to over 100% in the place of death analysis; and unsupported causal claims in the discussion. Conclusions: While the original study addresses an important public health concern, the identified methodological issues limit the interpretability of its findings. Addressing these concerns through consistent denominators, complete age‐stratified reporting and standard classifications would strengthen future research in this area.

20 February 2025
Verified
Preprint
Open access
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
WFWaliya Fatima
Waliya Fatima
SSSehar Saleem
Sehar Saleem
Antihistamines are commonly used to treat allergic diseases in children, such as rhinitis, asthma, and urticaria. They are classified into first and second-generation. First-generation antihistamines can cross the blood-brain barrier, causing significant sedation and other side effects, including new-onset seizures, poor academic performance, and paradoxical agitation. Recent studies show an increased risk of seizures, particularly in children aged 6 to 24 months. Although effective, first-generation antihistamines pose serious risks like sedation, cognitive impairment, and increased seizure risk. It is recommended to use newer, nonsedating antihistamines, which have fewer side effects. Children under six years old, especially those under two, should not be given first-generation antihistamines, particularly during flu season.

20 December 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
KRKinza Raza
Kinza Raza
HIHibba Mbbs Iftikhar
Hibba Mbbs Iftikhar
RMRaghabendra Kumar Mahato
Raghabendra Kumar Mahato
Anaphylaxis is a rapid-onset, potentially fatal allergic reaction that requires immediate epinephrine administration. Traditional intramuscular auto-injectors can be hindered by needle phobia, incorrect use, limited availability, and injection-related injuries. Neffy, the first FDA-approved intranasal epinephrine spray, provides a needle-free, rapid, and user-friendly alternative. Its nasal formulation allows swift absorption, producing pharmacodynamic effects within one minute, comparable to conventional auto-injectors. By eliminating needles, Neffy reduces the risk of lacerations, ischemic complications, and accidental injuries, while enhancing adherence among patients or caregivers hesitant to use injections. Early data indicate effective management of anaphylaxis with this device, though further studies in broader populations are warranted. Adoption of nasal epinephrine may improve timely treatment, increase accessibility, and offer a safer, patient-centered approach to emergency allergic reactions.

21 April 2026 in Cancer Treatment and Research Communications
Verified
Journal Article
Open access
PSPramod Singh
Pramod Singh
AZAsad Zaman
Asad Zaman
AHAli Shan Hafeez
Ali Shan Hafeez
AFAbdul Rafae Faisal
Abdul Rafae Faisal
MFMuhammad Faizan
Muhammad Faizan
AKAbat Khan
Abat Khan
Human herpesvirus-6 (HHV-6) infection is a known complication of allogeneic hematopoietic stem cell transplantation, but its incidence and clinical impact following chimeric antigen receptor T-cell (CAR-T) therapy remain unclear. A systematic review was conducted according to PRISMA 2020 guidelines to evaluate HHV-6 infection or reactivation after CAR-T therapy in adults. Searches of PubMed Central, Embase, and the Cochrane Library identified 50 records, of which 10 studies (five case reports, three case series, and two cohort studies) met inclusion criteria. Data on patient characteristics, timing, clinical manifestations, treatment, and outcomes were extracted and analyzed descriptively. Among 728 CAR-T recipients, HHV-6 infection or reactivation was reported in 22 patients (3.0%; 95% CI, 1.9%-4.5%) over a median follow-up of 2.8 months (range, 0.6-33.8). The median age was 56 years (range, 18-74), and 53.8% were male. HHV-6 infection occurred a median of 21 days (range, 16-84) after CAR-T infusion. Reported complications included encephalitis (n = 10), myelitis (n = 1), pancolitis (n = 1), and disseminated infection (n = 1). Antiviral therapy was administered in seven patients. Among 19 patients with available mortality data, 8 patients died from any cause (42.1%); 4 of these 8 deaths were attributed to HHV-6, corresponding to an HHV-6-attributable mortality of 21.1% among evaluable patients. Cytokine release syndrome was reported in all evaluable cases, and immune effector cell-associated neurotoxicity syndrome occurred in 11 of 17 patients. Although infrequent, HHV-6 infection or reactivation following CAR-T therapy is associated with substantial morbidity, particularly involving the central nervous system, and overlaps with CAR-T-related toxicities, underscoring the need for heightened clinical awareness.

11 April 2026 in American Heart Journal Plus: Cardiology Research and Practice
Verified
Journal Article
Open access
AQAhmar Jan Qureshi
Ahmar Jan Qureshi
MIMaryam Iftikhar
Maryam Iftikhar
RMRaghabendra Kumar Mahato
Raghabendra Kumar Mahato